Phase 1/1b, Open-Label, Dose-Escalation, Dose-Expansion, Parallel Assignment Study to Evaluate Safety and Clinical Activity of PBCAR0191 (Azercabtagene Zapreleucel or "Azer-cel") in Subjects with Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Protocol No
PRECISION-PBCAR0191-01
Staff Member
Nirav Shah
Phase
I
Summary

The purpose of this research study is to obtain information on the safety and effectiveness of
PBCAR0191 to treat certain types of cancers, such as Non-Hodgkin Lymphoma and B-cell
Acute Lymphoblastic Leukemia.
Objective
Dose-escalation, Dose-expansion Study of Safety of PBCAR0191 in Patients With r/r NHL B-cell
Study Sites
Froedtert Hospital
Status
OPEN TO ACCRUAL
Categories
Cancer, Hematologic/Blood Related Cancers, Other Blood Related
ClinicalTrials.gov
https://www.clinicaltrials.gov/study/NCT03666000